Metrics
2 Record Views
- Title
- A Phase 2 Response-Adapted Study of Daratumumab, Carfilzomib, and Dexamethasone (DKd) in Patients with High-Risk Smoldering Multiple Myeloma
- Creators
- Roshani Patel - National Institutes of HealthAmrit Bhaskarla - National Institutes of HealthMax J Gordon - National Institutes of HealthMichael Emanuel - National Institutes of HealthDana I. Delgado ColonHao-Wei WangConstance M. Yuan - National Institutes of HealthLiza Lindenberg - Center for Cancer ResearchEsther Mena - National Institutes of HealthBaris Turkbey - National Cancer InstituteNick Micheletti - National Institutes of HealthLaura M Yee - National Institutes of HealthNisha Patel - National Institutes of Health Clinical CenterIrina Maric - National Institutes of Health Clinical CenterRaul C. Braylan - National Institutes of Health Clinical CenterKatherine R. Calvo - National Institutes of Health Clinical CenterLouis M. Staudt - National Institutes of HealthRyan M. Young - National Institutes of HealthMark Roschewski - National Cancer InstituteDickran Kazandjian - University of MiamiElizabeth Hill - National Cancer Institute
- Publication Details
- Blood, Vol.144(Supplement 1), pp.7059-7059
- Academic Unit
- Miller School of Medicine; UMMG Dept of Medicine - Hematology/Oncology
- Language
- English
- Resource Type
- Journal article
- Record Identifier
- 991032518692402976